| Identification | Back Directory | [Synonyms]
AN152
AEZS 108
Batifiban
ZOPTARELIN DOXORUBICIN
OOUACICUAVTCEC-LZHWUUGESA-N
AEZS 108; AEZS108; ZOPTARELIN DOXORUBICIN; AN 152; AN-152; AN152
Luteinizing hormone-releasing factor (swine), 6-[N6-[5-[2-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-oxoethoxy]-1,5-dioxopentyl]-D-lysine]- | [MDL Number]
MFCD25977754 | [MOL File]
139570-93-7.mol |
| Hazard Information | Back Directory | [Uses]
Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis in vitro[1]. | [in vivo]
Zoptarelin doxorubicin (AN-152) inhibits tumor growth in glioblastoma xenograft mice[1]. | Animal Model: | Female nude mice (injected in the flanks with 1×106 glioblastoma U-87 MG cells)[1] | | Dosage: | 413 nM/20g | | Administration: | i.v.; once weekly; for 6 weeks | | Result: | Significantly inhibited tumor growth compared to the control. |
| [References]
[1] Jaszberenyi M, et al. Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Oncotarget. 2013 Mar;4(3):422-32. DOI:10.18632/oncotarget.917 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
m.approvedhomemanagement.com/ShowSupplierProductsList15748/0_EN.htm |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|